Welcome to our dedicated page for Pavmed news (Ticker: PAVMZ), a resource for investors and traders seeking the latest updates and insights on Pavmed stock.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) generates frequent news as a diversified commercial-stage medical technology company active in medical devices, diagnostics, and digital health. This news page aggregates press releases, market announcements, and other coverage related to PAVmed’s common stock and its Series Z warrants trading under the symbol PAVMZ.
Company updates often focus on the performance and milestones of its subsidiaries, particularly Lucid Diagnostics Inc. and Veris Health Inc. Lucid Diagnostics regularly reports on EsoGuard Esophageal DNA Test volumes, related revenue, clinical evidence packages, and developments in commercial coverage and reimbursement. Veris Health news commonly addresses progress on the Veris Cancer Care Platform, pilot programs with cancer centers, financing activities, and advancement of its implantable physiological monitor.
Investors following PAVMZ-related news can also expect announcements on quarterly and annual financial results, non-GAAP performance measures, and business update conference calls and webcasts. PAVmed frequently issues releases detailing business updates for specific quarters, including comments from management on strategy, subsidiary performance, and capital structure.
Regulatory and listing developments are another recurring theme. News items have covered PAVmed’s efforts to regain or maintain compliance with Nasdaq listing standards, including stockholders’ equity and minimum bid price requirements, as well as actions such as debt restructuring and deconsolidation of Lucid Diagnostics.
By monitoring this news feed, readers can track how PAVmed’s medical device, diagnostics, and digital health activities evolve over time, how Lucid Diagnostics and Veris Health contribute to the overall business, and how capital markets and regulatory developments intersect with the PAVM and PAVMZ securities.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a diversified commercial-stage medical technology company, has announced a business update conference call and webcast scheduled for August 13, 2024, at 8:30 AM ET. During the call, Chairman and CEO Lishan Aklog, M.D., will provide an overview of the company's operations and growth strategy, while President and CFO Dennis McGrath will discuss second quarter 2024 financial results.
Investors can access the webcast through PAVmed's website or join the conference call by dialing 1-800-836-8184 (U.S.) or 1-646-357-8785 (international). The call name is "PAVmed Business Update". A 30-day replay will be available on the company's website following the call.
PAVmed (NASDAQ: PAVM) provided a business update and reported financial results for Q1 2024. The company held a webcast on May 14, 2024, to discuss the results. Lucid Diagnostics, a subsidiary, completed a $29.8 million Series B offering, securing key reimbursement milestones. Veris Health signed an MOU with The Ohio State's James Cancer Hospital. Financially, PAVmed reported $1.0 million in EsoGuard revenues, flat quarter-over-quarter but a 124% increase from Q1 2023. Operating expenses were $15.0 million with a GAAP net loss of $22.8 million. Cash reserves stood at $25.5 million as of March 31, 2024.
Lucid Diagnostics Inc., a cancer prevention medical diagnostics company, provided a business update and financial results for the first quarter of 2024. The company reported a 10% increase in EsoGuard test volume, a strengthened balance sheet after a $29.8 million Series B Preferred Stock Offering, and a MolDX pre-submission meeting scheduled for July 17, 2024. Lucid also highlighted revenue growth, clinical study outcomes, and market access strategy.
Lucid Diagnostics Inc. announced that the EsophaCap sponge-on-a-string esophageal cell collection device has been subjected to a Class II FDA recall due to serious device failures reported. Lucid's EsoCheck® remains unaffected by the recall and continues to be the gold standard for non-endoscopic cell collection. The recall stemmed from two serious device failures reported in a recent publication of one of the studies using the EsophaCap device. Lucid's EsoCheck® is a modern technology enabling precise, targeted cell collection for esophageal precancer testing, offering unprecedented early precancer detection without causing any serious adverse events.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) will host a business update conference call and webcast on May 14, 2024, at 8:30 AM ET. During the call, PAVmed's CEO will provide an overview of operations and growth strategy, while the CFO will discuss the first quarter 2024 financial results.
Lucid Diagnostics, a cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc., will hold a business update conference call and webcast on May 13, 2024, at 8:30 AM ET. The call will feature Lucid's CEO providing an operational overview and growth strategy, along with the CFO discussing first-quarter 2024 financial results. Investors can access the webcast on the company's website or join via telephone.
Summary not available.
Summary not available.
Summary not available.
Summary not available.